CN1294582A - 新的核酸转移试剂,含有它们的组合物及其应用 - Google Patents

新的核酸转移试剂,含有它们的组合物及其应用 Download PDF

Info

Publication number
CN1294582A
CN1294582A CN99804274A CN99804274A CN1294582A CN 1294582 A CN1294582 A CN 1294582A CN 99804274 A CN99804274 A CN 99804274A CN 99804274 A CN99804274 A CN 99804274A CN 1294582 A CN1294582 A CN 1294582A
Authority
CN
China
Prior art keywords
group
compound
nucleic acid
formula
centimetres
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99804274A
Other languages
English (en)
Chinese (zh)
Inventor
G·柏克
M·弗莱德里克
H·霍夫兰德
D·斯彻尔曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9804121A external-priority patent/FR2777017B1/fr
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of CN1294582A publication Critical patent/CN1294582A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C07D239/14—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
CN99804274A 1998-04-02 1999-03-30 新的核酸转移试剂,含有它们的组合物及其应用 Pending CN1294582A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR98/04121 1998-04-02
FR9804121A FR2777017B1 (fr) 1998-04-02 1998-04-02 Nouveaux agents de transfert d'acides nucleiques, compositions les contenant et leurs applications
US8584598P 1998-05-18 1998-05-18
US60/085,845 1998-05-18

Publications (1)

Publication Number Publication Date
CN1294582A true CN1294582A (zh) 2001-05-09

Family

ID=26234240

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99804274A Pending CN1294582A (zh) 1998-04-02 1999-03-30 新的核酸转移试剂,含有它们的组合物及其应用

Country Status (12)

Country Link
EP (1) EP1068188A1 (ko)
JP (1) JP2002513543A (ko)
KR (1) KR20010042318A (ko)
CN (1) CN1294582A (ko)
AU (1) AU759301B2 (ko)
BR (1) BR9909350A (ko)
CA (1) CA2324931A1 (ko)
HU (1) HUP0102455A3 (ko)
IL (1) IL138625A0 (ko)
NO (1) NO317225B1 (ko)
PL (1) PL342886A1 (ko)
WO (1) WO1999051581A1 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020091242A1 (en) 2000-10-11 2002-07-11 Michel Bessodes Acid-sensitive compounds, their preparation and uses
ITMI20050222A1 (it) 2005-02-15 2006-08-16 Milano Politecnico Lipidi cationici per la trasfezione di acidi nucleici

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2645866B1 (fr) * 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
FR2714830B1 (fr) * 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2727679B1 (fr) * 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
FR2741066B1 (fr) * 1995-11-14 1997-12-12 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
CZ295225B6 (cs) * 1996-03-01 2005-06-15 Centre National De La Recherche Scientifique Amidiniový derivát a farmaceutický prostředek tento derivát obsahující

Also Published As

Publication number Publication date
NO20004780D0 (no) 2000-09-25
EP1068188A1 (fr) 2001-01-17
AU3406100A (en) 2000-11-30
NO317225B1 (no) 2004-09-20
JP2002513543A (ja) 2002-05-14
IL138625A0 (en) 2001-10-31
KR20010042318A (ko) 2001-05-25
AU759301B2 (en) 2003-04-10
WO1999051581A1 (fr) 1999-10-14
HUP0102455A3 (en) 2003-09-29
NO20004780L (no) 2000-11-01
PL342886A1 (en) 2001-07-16
CA2324931A1 (fr) 1999-10-14
HUP0102455A2 (hu) 2001-10-28
BR9909350A (pt) 2000-12-12

Similar Documents

Publication Publication Date Title
CN1131208C (zh) 化合物、它们的制备及其在细胞中核酸转移的应用
CN1210290C (zh) 核酸的送递
CN1051083C (zh) 有免疫调节活性的新的取代嘌呤基衍生物
CN1022411C (zh) 含氮环状配合物的制备方法
CN1151258C (zh) 通过内源基因活化制备促红细胞生成素
CN1047078A (zh) 用作兴奋性基酸神经递质拮抗物和/或钙通道阻滞剂的聚胺和多肽
CN1106806A (zh) 粘结受体拮抗剂iii
CN1527726A (zh) 红细胞生成素共轭物
CN1433478A (zh) 用于基因治疗的新的胶体合成载体
CN101061231A (zh) TNFR－Ig融合蛋白的生产
CN1596302A (zh) 细胞培养方法
CN1147260A (zh) 神经激肽(快速激肽)拮抗剂
CN1440396A (zh) 作为血管生成抑制剂的秋水仙醇衍生物
CN1906308A (zh) 小干扰rna的细胞转染制剂、相关组合物以及制备和使用方法
CN101048512A (zh) 抗淀粉样β肽抗体的生产
CN87106452A (zh) 新的头孢烯类化合物及其制备方法
CN1278790A (zh) 化合物
CN1079957A (zh) 可用于射线照相法对照产物的化合物
CN1596310A (zh) 产生重组多肽的方法
CN1150189C (zh) 用作整联蛋白抑制剂的苯并吡喃酮和苯并二氢吡喃酮衍生物
CN101062952A (zh) 由人血清白蛋白和干扰素组成的融合蛋白及其编码基因与应用
CN88101000A (zh) 泰可菌素化合物的取代的烷基酰胺类
CN1099040A (zh) 线性粘合抑制剂
CN1108261A (zh) 具有抗病毒作用的新的假肽
CN85105429A (zh) 制备脱糖太科普兰宁(deglucoteicoplanin)的羧酸酯衍生物的方法

Legal Events

Date Code Title Description
BB1A Publication of application
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
C20 Patent right or utility model deemed to be abandoned or is abandoned